Bavarian Nordic considers partnerships as essential part of our
business model.
We are open to the full range of set-ups from in-licensing,
out-licensing to sophisticated partnerships.
Bavarian Nordic owns a broadly applicable MVA-BN® vaccine
platform technology, which can be applied to develop multiple
vaccines across various disease areas, tested in more than 2,800
persons.
We can offer out-licensing opportunities of our proprietary
technologies and/or vaccine programmes and we search for
innovative technologies supplementing our in-house technologies and
programmes.
Bavarian Nordic is dedicated to three therapeutic areas, cancer, biodefence and infectious
diseases.
We are also interested in research collaborations with academic
groups and biotech companies. We might be able to provide
technologies and production know-how that your organization can use
to explore scientific arenas that lay beyond your available
resources and skills.
